New vaccine aims to keep leukemia at bay after transplant
NCT ID NCT03679650
First seen Jan 31, 2026 · Last updated Apr 25, 2026 · Updated 12 times
Summary
This early-phase trial tests a custom-made cancer vaccine (DC/AML fusion) for people with acute myeloid leukemia who have already had a stem cell transplant. The vaccine is designed to train the immune system to find and attack any remaining leukemia cells. Some participants also receive a low-dose chemotherapy drug (decitabine) to boost the vaccine's effect. The study involves 28 adults and focuses on safety and immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.